

CD8-TARGETED IL-2 DRIVES POTENT ANTI-TUMOR EFFICACY AND PROMOTES ACTION OF TUMOR SPECIFIC VACCINES

36th Annual Meeting
Society for the Immunotherapy of Cancer
Washington DC
November 13, 2021

Robert D. Schreiber, PhD.

Andrew M. and Jane M. Bursky Distinguished Professor


Interim Chief Division of Immunobiology

Department of Pathology and Immunology, Washington University in St. Louis


Director, Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs





Immune Checkpoint Therapy Eliminates T3 Sarcomas Via Mechanisms Requiring CD4⁺ and CD8⁺ T Cells and IFN γ



α -PD-1 Monotherapy is Not Effective Against “8 day Established” T3 Tumors




A Cis-Targeted IL-2 Mutein (CD8-IL-2) Allows for Selective Delivery of an IL-2 Signal to CD8⁺ T Cells




See Poster # 717 for additional information

Signaling



Expansion



CD8-Directed Cis-Targeted IL-2 Mutein Overcomes α -PD-1 Resistance and Synergizes with α -PD-1 in Late-Stage T3 Tumors

